GlassScriptPhysician profile
Julia Shor
NPI 1104215896
$864.31
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $96.88 · 2021: $671 · 2022: $96.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.57 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.81 | 2021 | |
| Celgene Corporation | $111.04 | 2021-2022 | |
| Braintree Laboratories, INC. | $84.27 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.06 | 2021 | |
| Janssen Biotech, INC. | $49.71 | 2021 | |
| Merck Sharp & Dohme LLC | $45.41 | 2020 | |
| Intercept Pharmaceuticals, INC. | $35.19 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $31.84 | 2021 | |
| Redhill Biopharma INC. | $24.23 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Shor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.